Keyphrases
Combination of Therapies
100%
Immune Checkpoint Therapy
100%
MiT Family Translocation Renal Cell Carcinoma
100%
Vascular Endothelial Growth Factor
42%
Targeted Therapy
42%
Translocation Renal Cell Carcinoma
28%
Fluorescence in Situ Hybridization
14%
Objective Response Rate
14%
Therapy Groups
14%
Metastatic Disease
7%
Effective Therapy
7%
Overall Survival
7%
Median Overall Survival
7%
Combination Therapy
7%
Response Evaluation Criteria in Solid Tumors (RECIST)
7%
Progression-free Survival
7%
Kaplan-Meier Method
7%
Median Progression-free Survival
7%
France
7%
Lack of Response
7%
First-line Therapy
7%
Paucity
7%
Biological Underpinnings
7%
M-ratio
7%
Belgium
7%
Transcription Factor E3 (TFE3)
7%
TFEB nuclear Translocation
7%
Pharmacology, Toxicology and Pharmaceutical Science
Vasculotropin
100%
Renal Cell Carcinoma
100%
Combination Therapy
100%
Retrospective Study
33%
Overall Survival
33%
Progression Free Survival
33%
Metastasis
16%
Biochemistry, Genetics and Molecular Biology
Immune Checkpoints
100%
Vascular Endothelial Growth Factor
42%
Fluorescence in Situ Hybridization
14%
Overall Survival
14%
Retrospective Study
14%
Progression Free Survival
14%
TFE3
7%
TFEB
7%